NNC0487-0111 for Weight Loss in People With Excess Weight and Sleep Apnoea
Tests NNC0487-0111 against placebo in adults with excess weight and sleep apnoea.
Plain-language title generated from the registry record
Registry title: AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Key facts
- Where
- Chiayi City, Taipei, and Taoyuan, TaiwanSee the 5 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with excess body weight and moderate-to-severe obstructive sleep apnoea who are not treated with positive airway pressure.
- Age
- 18 years or older
- Sex
- Men and women (sex at birth)
- Disease stage
- Previously diagnosed moderate-to-severe obstructive sleep apnoea with an AHI of 15 or more, shown by a sleep study or other method that meets local guidelines
- Earlier treatment
- People who had treatment with GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists (or any other GLP-1 based treatment) or amylin analogues before screening cannot join.
Main reasons for not taking part
- HbA1c of 6.5% (48 mmol/mol) or higher at screening
- History of type 1 or type 2 diabetes
- Planned or previous sleep apnoea surgery within 90 days before screening, including ear, nose and throat surgeries
- Significant face or skull abnormalities that may affect breathing
- Treatment with GLP-1 based drugs or amylin analogues before screening
Read by machine on 13 November 2026.
Where in Taiwan
- Ditmanson Medical Foundation Chia-Yi Christian HospitalChiayi City, TaiwanContact: Novo NordiskNot yet recruiting
- Cathay General HospitalTaipei, TaiwanContact: Novo NordiskTaking people
- Taipei Medical University HospitalTaipei, TaiwanContact: Novo NordiskTaking people
- Taipei Municipal Wan Fang Hospital_Division of OtorhinolaryngologyTaipei, TaiwanContact: Novo NordiskTaking people
- Chang Gung Memorial Hospital, LinkouTaoyuan, TaiwanContact: Novo NordiskTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07571005EU 2024-520442-36-00
- Record updated
- 11 September 2026
- Original description
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.Read full original descriptionShow less
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure (AMAZE 3)
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.
Inclusion: Male or female (sex at birth); Age 18 years or above at the time of signing informed consent; Previously diagnosed moderate-to-severe OSA with an AHI ≥ 15, as diagnosed with polysomnography (PSG), home sleep apnoea test (HSAT), or other method that meets local guidelines prior to screening.
Exclusion: Any planned or previous surgery within 90 days prior to screening for sleep apnoea, including septoplasty, turbinoplasty, or other ear, nose, and throat surgeries, including tonsillectomy and adenoidectomy; Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonist (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening; History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records; Significant craniofacial abnormalities that may affect breathing at baseline, for example Treacher Collins syndrome and Pierre Robin Sequence; Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening.